FDA Approves UCB’s Cimzia For Active Psoriatic Arthritis

UCB Inc. Sept. 30 announced that the Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA).

PsA is a chronic, inflammatory condition that causes pain, swelling and stiffness in and around the joints and tendons, and usually occurs in combination with psoriasis, the company said. UCB, a Belgian drug company, has U.S. offices in Smyrna, Ga.

“This approval represents the third indication for Cimzia in the U.S. and reaffirms the value of our commitment to developing medicines that treat serious, chronic diseases, and in turn help those with PsA,” ...